Results 221 to 230 of about 1,612,068 (309)
Copper homeostasis and cuproptosis in central nervous system diseases. [PDF]
Zhu Z +5 more
europepmc +1 more source
ABSTRACT The ascent of novel alternative methods in drug development spotlights the dual needs for improved biological fidelity to in vivo, along with reproducibility, especially in regulatory applications. The need for pre‐clinical models of patient‐derived endometriosis lesions motivates the development of a vascularizable, completely synthetic ...
Lauren Pruett +7 more
wiley +1 more source
Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles. [PDF]
Zou Y +5 more
europepmc +1 more source
This research shows the development of hydrogels with Diels‐Alder click chemistry for engineering cartilage‐like tissue. The hydrogels support cartilage spheroids which could be cultured for at least 28 days. Furthermore, the spheroids showed a tendency to fuse together into a more consistent construct, and produced important components needed for ...
Sanne M. van de Looij +8 more
wiley +1 more source
Piezo1: the key regulators in central nervous system diseases. [PDF]
Xu Y +7 more
europepmc +1 more source
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
Correction to: Interplay between androgen and CXCR4 chemokine signaling in myelin repair
Narimene Asbelaoui +7 more
doaj +1 more source
Ozone: complicated effects in central nervous system diseases. [PDF]
Zhang X, Wang SJ, Wan SC, Li X, Chen G.
europepmc +1 more source

